Finally, because mutations in GBA1 are the most common genetic risk factor for PD andaugmentation of its activity ameliorates symptoms in PD preclinicalmodels, we envision that an improved understanding of the regulationof lysosomal GCase activity should open new therapeutic avenues toaugment its activity. This evidence concerns the gene GBA1 and Parkinson disease.